Insulet touts real-world data for Omnipod insulin management tech


InsuletInsulet (NSDQ:PODD) touted real-world data today for its Omnipod insulin management system at the Congress of the European Association for the Study of Diabetes.

The data come from a study of nearly 39,000 patients with Type I and Type II diabetes who received insulin through the Omnipod system and had at least three months of data downloaded from Glooko’s cloud-based diabetes data management system.

Data showed that this use was linked with frequent fingerstick blood glucose testing using Abbott‘s (NYSE:ABT) integrated FreeStyle glucose meter, as well as high usage of the advanced features of Insulet’s Omnipod system, the company reported.

Get the full story on our sister publication Drug Delivery Business. 

Want to stay on top of MDO content? Subscribe to our e-newsletter.

Speak Your Mind